Hypoparathyroidism Market To Grow By USD 474.9 Million From 2024-2028, Driven By Thyroid Treatment Awareness Programs And AI-Powered Market Insights - Technavio

• 1.1 Parathyroid hormone
• 1.2 Vitamin D analogue
• 1.3 Calcium supplement
• 1.4 Others

• 2.1 Hospital pharmacy
• 2.2 Retail pharmacy
• 2.3 Online pharmacy

• 3.1 North America
• 3.2 Europe
• 3.3 Asia
• 3.4 Rest of World (ROW)

1.1
Parathyroid hormone-
The hypoparathyroidism market is driven by the development and approval of Parathyroid Hormone (PTH) therapies. Despite a recent setback with the FDA, the European Commission approved YORVIPATH in November 2023 for chronic hypoparathyroidism. Hypoparathyroidism is a condition characterized by parathyroid gland dysfunction, leading to deficiency in parathyroid hormone, causing hypocalcemia, hyperphosphatemia, and neuromuscular irritability. Symptoms include muscle pain, spasms , twitching, seizures, and tetany. Iatrogenic injury during head and neck surgeries is a common cause. PTH therapies are crucial for managing these symptoms and improving patient outcomes. The European approval of Yorvipath sets a precedent for other regions, potentially leading to increased adoption of PTH therapies globally. Pharmaceutical companies invest in innovative solutions to address the unmet needs of hypoparathyroidism patients, driving market growth. In conclusion, regulatory approvals and new therapies are advancing the PTH segment within the hypoparathyroidism market, crucial for improving patient care and managing complex symptoms. The focus on PTH therapies will remain a key driver of growth and innovation in the industry.

Download a Sample
of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of Parathyroid Hormone (PTH) leading to low calcium and high phosphate levels in the body. The treatment market for hypoparathyroidism includes calcium supplements, vitamin D analogues, and hormonal therapy. Calcium supplements help maintain normal calcium levels, while vitamin D analogues enhance calcium absorption. Hormonal therapy involves the use of PTH or its analogues to restore normal calcium homeostasis. Calcitriol, a form of vitamin D, is also used to increase calcium absorption. Treatment for hypoparathyroidism can be oral, parenteral, or surgical, depending on the severity of the condition. Hospitals, homecare, and specialty centers are common settings for the administration of these treatments. Thyroid surgery, particularly thyroidectomy, can cause hypoparathyroidism as a complication. The condition can be idiopathic, hereditary, or autoimmune in origin. Diagnosis of hypoparathyroidism involves measuring serum calcium levels, serum phosphorus levels, albumin-corrected total calcium, and plasma parathyroid hormone levels. Serum magnesium levels may also be measured as low magnesium levels can exacerbate symptoms of hypoparathyroidism. Postoperative complications following thyroid surgery can also lead to hypoparathyroidism. Genetic conditions and autoimmune destruction of the parathyroid glands are other causes of the disorder.

Market Research Overview

Hypoparathyroidism is a rare endocrine disorder characterized by insufficient production of parathyroid hormone (PTH), leading to low calcium and high phosphate levels in the body. The treatment market for hypoparathyroidism includes various options such as calcium supplements, vitamin D analogues, calcitriol, hormonal therapy, and biologics. These medications aim to maintain normal calcium and phosphate levels, prevent hypocalcemia, and manage associated complications like osteosarcoma and postoperative complications following thyroidectomy. The hypoparathyroidism market landscape is diverse, with treatments available in various forms including oral, parenteral, and surgical options. Hospitals, homecare , specialty centers, hospital pharmacies, online pharmacies, and retail pharmacies are key channels for medication distribution. Patient epidemiology and demographics play a significant role in the market, with an estimated 1 in 2,000 people affected by hypoparathyroidism. Diagnosis involves assessing serum calcium levels, serum phosphorus levels, albumin-corrected total calcium, plasma parathyroid hormone, and serum magnesium. The biopharma industry is focusing on personalized medicines, emerging therapies, and drug recalls to cater to the unique needs of hypoparathyroidism patients. Clinical trials are ongoing to explore new treatment options, including Fast Track Designation for some therapies. Challenges in the market include the high cost of treatment, potential side effects, and the need for long-term management. A black box warning for certain medications highlights the importance of careful monitoring and patient education. Patient awareness and advocacy efforts are crucial in managing hypoparathyroidism, with organizations promoting patient support, education, and research. The market is expected to grow due to the increasing prevalence of hypoparathyroidism, advances in treatment options, and the rising demand for personalized medicines.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

• Product
  • Parathyroid Hormone
  • Vitamin D Analogue
  • Calcium Supplement
  • Others
• Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
• Geography
  • North America
  • Europe
  • Asia
  • Rest Of World (ROW)

7
Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:
[email protected]
Website:

SOURCE Technavio

MENAFN04112024003732001241ID1108849313